Cotellic

Question 1

Is Zelboraf safe to use during pregnancy?

Accepted Answer

Zelboraf can potentially cause harm to a fetus when used by pregnant women. Limited data is available, but placental transfer to the fetus has been reported. Pregnant women should be informed of the potential risks to the fetus.

Question 2

Are there risks associated with breastfeeding while using Zelboraf?

Accepted Answer

No information exists regarding the presence of Zelboraf in human milk or its effects on infants or milk production. Due to potential adverse reactions in infants, including serious conditions like malignancy and dermatologic reactions, women are advised not to breastfeed during Zelboraf treatment and for 2 weeks after the final dose.

Question 3

What precautions should females and males of reproductive potential take while using Zelboraf?

Accepted Answer

Females of reproductive potential should use effective contraception during Zelboraf treatment and for 2 weeks after the last dose due to the potential risk of fetal harm. Males should also take precautions, and those with female partners of reproductive potential should use condoms during treatment and for 2 weeks after the last dose.

Question 4

Is Zelboraf approved for use in pediatric patients?

Accepted Answer

The safety and effectiveness of Zelboraf in pediatric patients have not been fully established, although limited studies were conducted in adolescents with specific melanoma types. Further research is needed to determine its safety profile in this population.

Question 5

What information is available regarding Zelboraf use in older adults?

Accepted Answer

Clinical studies for Zelboraf did not include enough elderly subjects to determine if they respond differently from younger individuals.

Question 6

Are there recommended dosage adjustments for patients with liver or kidney impairment?

Accepted Answer

For patients with mild or moderate liver or kidney impairment, no dosage adjustment is recommended based on available analyses. However, the appropriate dose has not been established for patients with severe impairment in these organs.

Cotellic [Cotellic + Zelboraf]